Infertility treatments during pregnancy and the risk of autism Spectrum disorder in the offspring

Michael Davidovitch; Gabriel Chodick; Varda Shalev; Vered H. Eisenberg; Uzi Dan; Abraham Reichenberg; Sven Sandin; Stephen Z. Levine

doi:10.1016/j.pnpbp.2018.05.022

Infertility treatments during pregnancy and the risk of autism Spectrum disorder in the offspring

Michael Davidovitch, Gabriel Chodick, Varda Shalev, Vered H. Eisenberg, Uzi Dan, Abraham Reichenberg, Sven Sandin, Stephen Z. Levine

Department of Community Mental Health

Research output: Contribution to journal › Article › peer-review

Abstract

We aimed to examine the effects of infertility treatments on the risk of Autism Spectrum Disorder (ASD). Data were from a representative national registry on 110,093 male live births in Israel (born: 1999–2008; and ASD: 975, 0.9%). Infertility treatments included In Vitro Fertilization (IVF), and five hormone treatments. Relative risk (RR) was estimated with multivariable logistic models. Results showed that IVF treatment compared with spontaneous conception was not statistically significantly associated with the risk of ASD. Only progesterone hormone treatment was associated with a statistically significant (p <.05) increased risk of ASD (RR = 1.51, 95% CI 1.22, 1.86) compared to the group with no progesterone treatment. In conclusion, progesterone exposure during the critical period of fetal life elevated the risk of ASD, possibly reflecting epigenetic modification.

Original language	English
Pages (from-to)	175-179
Number of pages	5
Journal	Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume	86
DOIs	https://doi.org/10.1016/j.pnpbp.2018.05.022
State	Published - 30 Aug 2018

Bibliographical note

Funding Information:
This study was supported by Maccabi Healthcare research grant 45777 to author Levine at the University of Haifa , and in part by the Seaver Foundation ; Sven Sandin, PhD, is a Seaver Faculty Scholar.

Funding Information:
Levine has received research support, and/or consultancy fees and/or travel support from Shire, F. Hoffmann-La Roche and Eli Lilly, which are all unrelated to this research. Shalev and Chodick were funded by Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv Israel. Authors Davidovitch, Chodick, Shalev, Eisenberg and Dan are employees of Maccabi Healthcare Service. The remaining authors declare no conflict of interest.

Funding Information:
This study was supported by Maccabi Healthcare research grant 45777 to author Levine at the University of Haifa, and in part by the Seaver Foundation; Sven Sandin, PhD, is a Seaver Faculty Scholar.

Publisher Copyright:
© 2018 Elsevier Inc.

Keywords

Autism Spectrum disorders
Epidemiology
Hormone
Infertility

ASJC Scopus subject areas

Pharmacology
Biological Psychiatry

Access to Document

10.1016/j.pnpbp.2018.05.022

Cite this

@article{cde8d83aad8748b8abf620cd87a5f29a,

title = "Infertility treatments during pregnancy and the risk of autism Spectrum disorder in the offspring",

abstract = "We aimed to examine the effects of infertility treatments on the risk of Autism Spectrum Disorder (ASD). Data were from a representative national registry on 110,093 male live births in Israel (born: 1999–2008; and ASD: 975, 0.9%). Infertility treatments included In Vitro Fertilization (IVF), and five hormone treatments. Relative risk (RR) was estimated with multivariable logistic models. Results showed that IVF treatment compared with spontaneous conception was not statistically significantly associated with the risk of ASD. Only progesterone hormone treatment was associated with a statistically significant (p <.05) increased risk of ASD (RR = 1.51, 95% CI 1.22, 1.86) compared to the group with no progesterone treatment. In conclusion, progesterone exposure during the critical period of fetal life elevated the risk of ASD, possibly reflecting epigenetic modification.",

keywords = "Autism Spectrum disorders, Epidemiology, Hormone, Infertility",

author = "Michael Davidovitch and Gabriel Chodick and Varda Shalev and Eisenberg, {Vered H.} and Uzi Dan and Abraham Reichenberg and Sven Sandin and Levine, {Stephen Z.}",

note = "Funding Information: This study was supported by Maccabi Healthcare research grant 45777 to author Levine at the University of Haifa , and in part by the Seaver Foundation ; Sven Sandin, PhD, is a Seaver Faculty Scholar. Funding Information: Levine has received research support, and/or consultancy fees and/or travel support from Shire, F. Hoffmann-La Roche and Eli Lilly, which are all unrelated to this research. Shalev and Chodick were funded by Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv Israel. Authors Davidovitch, Chodick, Shalev, Eisenberg and Dan are employees of Maccabi Healthcare Service. The remaining authors declare no conflict of interest. Funding Information: This study was supported by Maccabi Healthcare research grant 45777 to author Levine at the University of Haifa, and in part by the Seaver Foundation; Sven Sandin, PhD, is a Seaver Faculty Scholar. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = aug,

day = "30",

doi = "10.1016/j.pnpbp.2018.05.022",

language = "English",

volume = "86",

pages = "175--179",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier",

}

TY - JOUR

T1 - Infertility treatments during pregnancy and the risk of autism Spectrum disorder in the offspring

AU - Davidovitch, Michael

AU - Chodick, Gabriel

AU - Shalev, Varda

AU - Eisenberg, Vered H.

AU - Dan, Uzi

AU - Reichenberg, Abraham

AU - Sandin, Sven

AU - Levine, Stephen Z.

N1 - Funding Information: This study was supported by Maccabi Healthcare research grant 45777 to author Levine at the University of Haifa , and in part by the Seaver Foundation ; Sven Sandin, PhD, is a Seaver Faculty Scholar. Funding Information: Levine has received research support, and/or consultancy fees and/or travel support from Shire, F. Hoffmann-La Roche and Eli Lilly, which are all unrelated to this research. Shalev and Chodick were funded by Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv Israel. Authors Davidovitch, Chodick, Shalev, Eisenberg and Dan are employees of Maccabi Healthcare Service. The remaining authors declare no conflict of interest. Funding Information: This study was supported by Maccabi Healthcare research grant 45777 to author Levine at the University of Haifa, and in part by the Seaver Foundation; Sven Sandin, PhD, is a Seaver Faculty Scholar. Publisher Copyright: © 2018 Elsevier Inc.

PY - 2018/8/30

Y1 - 2018/8/30

N2 - We aimed to examine the effects of infertility treatments on the risk of Autism Spectrum Disorder (ASD). Data were from a representative national registry on 110,093 male live births in Israel (born: 1999–2008; and ASD: 975, 0.9%). Infertility treatments included In Vitro Fertilization (IVF), and five hormone treatments. Relative risk (RR) was estimated with multivariable logistic models. Results showed that IVF treatment compared with spontaneous conception was not statistically significantly associated with the risk of ASD. Only progesterone hormone treatment was associated with a statistically significant (p <.05) increased risk of ASD (RR = 1.51, 95% CI 1.22, 1.86) compared to the group with no progesterone treatment. In conclusion, progesterone exposure during the critical period of fetal life elevated the risk of ASD, possibly reflecting epigenetic modification.

AB - We aimed to examine the effects of infertility treatments on the risk of Autism Spectrum Disorder (ASD). Data were from a representative national registry on 110,093 male live births in Israel (born: 1999–2008; and ASD: 975, 0.9%). Infertility treatments included In Vitro Fertilization (IVF), and five hormone treatments. Relative risk (RR) was estimated with multivariable logistic models. Results showed that IVF treatment compared with spontaneous conception was not statistically significantly associated with the risk of ASD. Only progesterone hormone treatment was associated with a statistically significant (p <.05) increased risk of ASD (RR = 1.51, 95% CI 1.22, 1.86) compared to the group with no progesterone treatment. In conclusion, progesterone exposure during the critical period of fetal life elevated the risk of ASD, possibly reflecting epigenetic modification.

KW - Autism Spectrum disorders

KW - Epidemiology

KW - Hormone

KW - Infertility

UR - http://www.scopus.com/inward/record.url?scp=85048157299&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2018.05.022

DO - 10.1016/j.pnpbp.2018.05.022

M3 - Article

C2 - 29864450

AN - SCOPUS:85048157299

SN - 0278-5846

VL - 86

SP - 175

EP - 179

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

ER -

Infertility treatments during pregnancy and the risk of autism Spectrum disorder in the offspring

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this